CM310
Phase 3Small molecule
CM310 is one of 90 small molecule programs targeting Adolescent. It is currently in Phase 3.
3
Indications
24
Total Trials
3
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1CM310
KKeymed Biosciences Co.Ltd
Phase 3
Celexa
AbbViePreclinical
Arcoxia
NovartisPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Paracetamol
GSKPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Ozone
TTanta University
Preclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis6 trials
Chronic Rhinosinusitis2 trials
Asthma2 trials
Adolescent2 trials
9 more indications
Children2 trials
Chronic Obstructive Pulmonary Disease1 trial
A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting·
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2/3·NCT06547333·884 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2/3·NCT06547333·884 enrolledIgG4 Related Disease1 trial
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
Unknown status·—·N/A·NCT05728684·20 enrolled
Chronic Rhinosinusitis With Nasal Polyps1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CM310. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- KKeymed Biosciences Co.Ltd